

Design, synthesis, and *in silico* ADME and anticancer evaluation of 4-amino-5-phenyl-1,2,4-triazole-3-thiol Schiff bases

Maitham M. Abdulridha¹, Bassam A. Hassan^{2*} and Fadil M. Hamed³

¹Department of Medical Lab, Shatra Technical College, Southern Technical University, Basra, Iraq.

²Department of Chemistry, College of Education, Al-Ayen Iraqi University, AUIQ, Nasiriyah, Thi-Qar, Iraq.

³University Presidency, Shatrah University, Shatrah, Thi-Qar, Iraq.

ABSTRACT A series of five new 4-amino-5-phenyl-1,2,4-triazole-3-thiol Schiff base derivatives (**4a-4e**) was rationally designed, and successfully synthesized by the condensation reaction between 4-amino-phenyl-4*H*-1,2,4-triazol-3-thiol and aromatic aldehydes, *in silico* absorption, distribution, metabolism, and excretion (ADME) studies were conducted using the Swiss ADME platform to assess drug-likeness and pharmacokinetic behavior. The predicted results indicated favorable physicochemical properties, good oral bioavailability, high gastrointestinal absorption, and compliance with Lipinski, Veber, and Egan rules, with no predicted blood-brain barrier permeability. The anticancer activity of the synthesized compounds was evaluated *in vitro* using MTT viability assay against the HepG2 human hepatocellular carcinoma cell line, with WRL-86 normal hepatic cells used for comparison. Compound **4a** exhibited a concentration-dependent cytotoxic effect against HepG2 cells, while showing comparatively lower toxicity toward WRL-68 cells, suggesting a possible degree of selectivity toward cancer cells. However, the observed anticancer activity was modest and was more pronounced only at higher concentrations. Overall, the combined synthetic, structure, *in silico* ADME, and preliminary biological evaluation indicated that these 1,2,4-triazole-based Schiff base derivatives represent promising scaffolds for further structure optimization and extended biological investigations.